Advances,controversies,and consensus in perioperative immunotherapy for lung cancer
10.12354/j.issn.1000-8179.2024.20240990
- VernacularTitle:肺癌围手术期免疫治疗的进展、争议与共识
- Author:
Jin LI
1
;
Zhou CAICUN
Author Information
1. 同济大学附属东方医院附属肿瘤科(上海市 200123)
- Keywords:
non-small cell lung cancer(NSCLC);
perioperative immunotherapy;
neoadjuvant and adjuvant treatment
- From:
Chinese Journal of Clinical Oncology
2024;51(16):817-821
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,perioperative immunotherapy for non-small cell lung cancer(NSCLC)has made significant progress.Several inter-national phase Ⅲ clinical trials(such as CheckMate-816,IMpower010 and KEYNOTE-091)have demonstrated that neoadjuvant and ad-juvant immunotherapy can significantly improve pathological response rates,event-free survival(EFS),and disease-free survival(DFS)in stage Ⅱ-Ⅲ NSCLC patients,leading to regulatory approvals worldwide.Further studies,including KEYNOTE-671,AEGEAN,and CheckMate-77T,have validated the potential advantages of the"neoadjuvant+adjuvant"immunotherapy approach,significantly reducing the risk of postoperative recurrence in certain populations.Additionally,biomarkers such as PD-L1 expression,minimal residual disease(MRD)status,and ctDNA monitoring are being investigated as predictive indicators to optimize individualized treatment strategies.However,there are still controversies regarding the choice of perioperative immunotherapy modes,the optimal treatment cycle,and the application in patients with driver gene mutations.Future research will continue to explore the efficacy of immunotherapy in different patient subgroups to maximize clinical benefits while minimizing the toxicity risks associated with treatment.
